E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Proliferative Diabetic Retinopathy (PDR) |
|
E.1.1.1 | Medical condition in easily understood language |
An advanced diabetic eye condition caused by abnormal growth of new blood vessels in the eye. |
|
E.1.1.2 | Therapeutic area | Body processes [G] - Ocular Physiological Phenomena [G14] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate whether mean change in best corrected visual acuity following intravitreal aflibercept therapy is non-inferior to panretinal photocoagulation (PRP) in eyes with proliferative diabetic retinopathy (PDR) at 52 weeks as measured by ETDRS letters. |
|
E.2.2 | Secondary objectives of the trial |
1.To measure the effect of intravitreal aflibercept therapy, relative to panretinal photocoagulation on additional visual functions and quality of life outcomes including i)Unilateral and Binocular Esterman visual fields defects ii)Binocular visual acuity iii)Low luminance visual acuity iv)Visual acuity outcomes in terms of visual gain or loss v)Contrast sensitivity using Pelli Robson charts vi)Vision-related quality of life measured by VFQ-25 and RetDQoL vii)Diabetic retinopathy treatment satisfaction outcomes (RetTSQ) viii)Generic health-related quality of life using the EQ-5D, ICECAP-A, and CSRI.
2.To estimate incremental cost-effectiveness of intravitreal aflibercept versus standard PRP treatment at 52 weeks.
3.To determine the proportions of naïvePDR and non-naïve PDR eyes in both arms that do not require panretinal photocoagulation through 52 weeks after basic treatment of 3 loading doses of aflibercept or initial completion of PRP. 4.To compare between a |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
Embedded in the CLARITY trial version 1 is a mechanistic sub-study. 40 participants will undergo retinal photography and image analysis at screening, 12 and 52 weeks to explore the effect of aflibercept on the retina and blood vessels. |
|
E.3 | Principal inclusion criteria |
1.Subjects of either sex aged 18 years or over. 2.Diagnosis of diabetes mellitus (type 1 or type 2). 3.Best corrected visual acuity in the study eye better than or equal to 54 ETDRS letters (Snellen visual acuity 6/24). Please see section 6.3 Re-screening of patients 4.Visual acuity in fellow eye ≥ 2/60 5.PDR with no evidence of previous PRP or presence of new or persistent retinal neovascularisation despite prior PRP that (a) requires treatment in the opinion of the investigator and (b) there is sufficient space in the peripheral retina to perform more PRP treatment. In patients with both eye involvement, the eye with no PRP or the least number of PRP burns will be randomised as the study eye. If both eyes have had no PRP before, the eye with the better visual acuity will be randomised as the study eye. However, patients will be offered a choice and can opt for the ‘worse seeing eye’ to be randomised 6.Media clarity, pupillary dilation and subject cooperation sufficient for adequate fundus photographs. Eyes with mild pre-retinal haemorrhage or mild vitreous haemorrhage that does not interfere with clear visualisation of the macula and optic disc are eligible for this study. 7.Ability to give informed consent 8.Women should use effective contraception, be post-menopausal for at least 12 months prior to trial entry, or surgically sterile
|
|
E.4 | Principal exclusion criteria |
1.Co-existent ocular disease that will affect visual outcome. 2.Moderate or dense vitreous haemorrhage that prevents clear visualisation of the macula and/or optic disc or prevents PRP treatment. 3.Significant fibrovascular proliferation or tractional retinal detachment in the posterior pole. 4.Prior vitrectomy. 5.Presence of macular oedema at baseline confirmed by 3D OCT-1000 (Topcon) SD-OCT as central subfield thickness of more than 300µm due to the presence of morphological evidence of diffuse or cystoid oedema. The equivalent measurement for Spectralis OCT is 320µm and Cirrus HD-OCT is 300µm. Please see rescreening of patients. 6.Other causes of retinal neovascularisation. 7.Iris or angle neovascularisation and neovascular glaucoma. 8.Anticipated need for cataract extraction or vitrectomy within the next 12 months. 9.Known allergy to fluorescein or any components of aflibercept formulation. 10.Previous intravitreal anti-VEGF or steroid treatment for diabetic macular oedema in the last 4 months. (Previous Iluvien therapy is an exclusion). 11.Panretinal photocoagulation within the last 8 weeks. 12.Aphakia. 13.Uncontrolled glaucoma as per investigator’s judgement. 14.Severe external ocular infection.
Exclusion criteria also apply to systemic conditions as follows:
15.The participant should not have an HbA1c level of more than 12%. Please see section 6.3 Re-screening of patients. 16.The participant should not have a blood pressure of more than 170/110mmHg. Please see section 6.3 Re-screening of patients. 17.A medical condition that, in the opinion of the investigator, would preclude participation in the study. 18.Myocardial infarction, stroke, transient ischaemic attack, acute congestive cardiac failure or any acute coronary event within 6 months of randomisation. 19.Dialysis or renal transplant. 20.Pregnant women. 21.Women of child bearing potential who do not agree to use effective contraception during the study and for at least 3 months after the study has finished. 22.Breast feeding women. 23.Males who do not agree to use an effective form of contraception for the duration of the study and for 3 months after the study has finished. 24.Participation in an investigational trial involving an investigational medicinal product within 30 days of randomisation.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
To evaluate whether mean change in best corrected visual acuity following intravitreal aflibercept therapy is non-inferior to panretinal photocoagulation (PRP) in eyes with proliferative diabetic retinopathy (PDR) at 52 weeks as measured by ETDRS letters. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Participants will have visual acuity tests at every visit, but best corrected visual acuity will be assessed at screening, week 12, week 52 and at the point of withdrawal. |
|
E.5.2 | Secondary end point(s) |
1.To measure the effect of intravitreal aflibercept therapy, relative to panretinal photocoagulation on additional visual functions and quality of life outcomes including i)Unilateral and Binocular Esterman visual fields defects ii)Binocular visual acuity iii)Low luminance visual acuity iv)Visual acuity outcomes in terms of visual gain or loss v)Contrast sensitivity using Pelli Robson charts vi)Vision-related quality of life measured by VFQ-25 and RetDQoL vii)Diabetic retinopathy treatment satisfaction outcomes (RetTSQ) viii)Generic health-related quality of life using the EQ-5D, ICECAP-A, and CSRI.
2.To estimate incremental cost-effectiveness of intravitreal aflibercept versus standard PRP treatment at 52 weeks.
3.To determine the proportions of naïvePDR and non-naïve PDR eyes in both arms that do not require panretinal photocoagulation through 52 weeks after basic treatment of 3 loading doses of aflibercept or initial completion of PRP.
4.To compare between arms the regression pattern at 12 weeks and the regression and reactivation patterns of retinal neovascularisation at 52 weeks.
5.To compare the proportion of patients with 1-step and 3-step improvement or worsening of diabetic retinopathy between treatment arms at 12 and 52 weeks as per schedule of assessment.
6.To explore the difference in safety profile between intravitreal aflibercept and panretinal photocoagulation at 52 weeks, in terms of proportion of patients developing macular oedema (defined as central subfield thickness of >300µm on 3DOCT-1000 (Topcon) SD-OCT due to clinical evidence of macular oedema) or Spectralis OCT >320µmor Cirrus HD-OCT >300 µm or its equivalent if any other OCT devices are used, any de novo or increase in existing vitreous haemorrhage, de novo or increasing tractional retinal detachment, neovascular glaucoma, and requirement for vitrectomy. The indication for vitrectomy will be reported.
Mechanistic evaluation objectives: 1.To explore whether intravitreal aflibercept compared to panretinal photocoagulation causes measurable regression of area of retinal neovascularisation at 12 and 52 weeks.
2.To explore differences in the mean change in retinal vessel oxygen saturation and retinal vessel calibre in eyes treated with intravitreal aflibercept compared to panretinal photocoagulation at 12 and 52 weeks.
3.To explore whether intravitreal aflibercept reduces angiographically quantifiable areas of retinal non-perfusion compared to panretinal photocoagulation through 52 weeks.
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1)& 2) Screening, week 52 and point of withdrawal. 3) Week 12, week 52 and point of withdrawal. 4), 5) & 6) Screening, week 12, week 52 and point of withdrawal.
Mechanistic evaluation 1), 2) and 3) Screening, week 12, week 52 and point of withdrawal. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | Yes |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
Panretinal procogulation laser treatment - standard care |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 17 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 1 |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 1 |